Marché nord-américain du diagnostic multiplex syndromique – Tendances et prévisions de l’industrie jusqu’en 2029

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché nord-américain du diagnostic multiplex syndromique – Tendances et prévisions de l’industrie jusqu’en 2029

  • Medical Devices
  • Publish Reports
  • May 2022
  • North America
  • 350 Pages
  • Nombre de tableaux : 61
  • Nombre de figures : 43

>Marché du diagnostic syndromique multiplex en Amérique du Nord - Par produit et services (réactifs et consommables, instruments, logiciels et accessoires et services), type d'infection (virale, bactérienne, parasitaire et fongique), maladie ( infections respiratoires , gastro-entérite, infections sexuellement transmissibles, septicémie , méningite et autres), type de panels (panel respiratoire, panel gastro-entérique, panel de maladies sexuellement transmissibles, panel de septicémie sanguine, panel de méningite et autres), utilisateur final (laboratoires cliniques, hôpitaux, sociétés pharmaceutiques et biotechnologiques, instituts de recherche et autres) Tendances et prévisions de l'industrie jusqu'en 2029.

Marché nord-américain du diagnostic syndromique multiplex

Définition et perspectives du marché

Le diagnostic multiplex syndromique est un type de test de diagnostic avancé utilisé pour détecter les maladies infectieuses telles que les infections respiratoires, la gastro-entérite infectieuse , les infections sexuellement transmissibles, la septicémie et la méningite, entre autres types de maladies infectieuses. Le diagnostic multiplex syndromique aide également les cliniciens ou les hôpitaux à détecter les symptômes et les signes des différents types de maladies. Cela permet aux prestataires de soins de santé de fournir le traitement approprié aux patients et d'offrir des résultats plus précis et des soins qui peuvent être effectués plus rapidement.

Marché du diagnostic multiplex syndromique

Marché du diagnostic multiplex syndromique

Les tests multiplex syndromiques sont utilisés pour diagnostiquer simultanément de nombreux agents pathogènes. Dans le diagnostic multiplex syndromique, différents types de réactifs et de consommables, ainsi que d'instruments et d'accessoires sont utilisés, ce qui permet de maintenir la précision et de fournir des résultats de diagnostic rapides. Ces tests multiplexés permettent de diagnostiquer rapidement certaines infections, ce qui permet de prendre rapidement des décisions de gestion clinique. Les tests basés sur la technologie multiplex sont connus sous le nom de panels de test. Les panels utilisés dans les tests syndromiques sont conçus pour diagnostiquer plusieurs maladies associées au même type de syndrome ou à un type de syndrome similaire. Ces panels aident à évaluer la cause de la maladie au point de service. Les panels gastro-intestinaux et les panels respiratoires sont les types de panels syndromiques.

Le test multiplex syndromique utilise la technologie avancée de la PCR multiplex qui fournit des résultats de diagnostic précis et rapides à l'aide des multiples panels utilisés dans le diagnostic multiplex syndromique pour fournir des résultats de diagnostic en une heure. Les nouvelles générations de multiplex syndromiques peuvent identifier rapidement le type commun d'agents pathogènes dans les échantillons respiratoires, sanguins et cérébro-spinaux. L'utilisation de panels multiplex est associée à un délai d'exécution plus rapide, à une réduction des autres tests de laboratoire inutiles, à un diagnostic plus rapide et à un traitement ciblé.

Data Bridge Market Research analyse que le marché nord-américain du diagnostic multiplex syndromique connaîtra un TCAC de 9,0 % au cours de la période de prévision de 2022 à 2029.

Rapport métrique

Détails

Période de prévision

2022 à 2029

Année de base

2021

Années historiques

2020

Unités quantitatives

Chiffre d'affaires en millions USD, volumes en unités, prix en USD

Segments couverts

Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others),  Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others),  End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others)

Countries Covered

U.S., Canada, and Mexico

Market Players Covered

BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Akonni Biosystems, Inc. (U.S.), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Applied BioCode, Inc. (U.S.), Prominex Inc. (U.S.), Nanomix, Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany)

Syndromic Multiplex Diagnostic Market Dynamics

Drivers

  • Rise in prevalence of infectious diseases

The rising incidence of infectious bacterial and viral diseases impacts the market's demand because, in the syndromic testing, multiplex real-time PCR technique and the syndromic approach are used for molecular diagnostics of infectious diseases.

  • Increase in regulatory approval for acute respiratory syndrome coronavirus testing

In May 2020, biomérieux SA received FDA Emergency Use Authorization (EUA) for the BIOFIRE RP2.1 panel, which is used for the detection of 22 pathogens which is causing respiratory infections, including SARS-CoV-2 for COVID-19 disease.

The regulatory authorities, such as the FDA or CE mark, provide Emergency Use Authorization (EUA) approval for commercializing SARS-CoV-2 panels and testing to detect viruses associated with COVID-19 disease, which is a driver for the growth of the market.

Opportunities

  • Strategic Initiatives taken by market players

In March 2021, F. Hoffman-La Roche Ltd acquired GenMark Diagnostics, a leading multiplex molecular diagnostics provider. This acquisition has helped the company to broaden Roche’s molecular diagnostic portfolio. These strategic initiatives taken by the market players, including focused segment product launches, are helping them expand their global reach and enhance their product portfolio and acting as an opportunity for the market's growth.

  • Introduction of technologically advanced products

The syndromic multiplex testing utilizes the advanced technology of multiplex PCR to detect, isolate, or amplify targeted nucleic acid to provide accurate and fast diagnostic results; the advanced technology provides a diagnostic result within 45 to 60 min.  Hence, the development of technologically advanced products is acting as an opportunity for the market's growth.

Restraint/Challenge

  • High Cost of Diagnostic Products

The multiplex syndromic testing applications utilize the real-time Polymerase chain reaction (PCR), which delivers the results with amplification curves and correct values. The instruments used in the syndromic multiplex diagnostic require high maintenance costs. Hence, the high cost of instruments is a challenge for the market.

Post COVID-19 Impact on Syndromic Multiplex Diagnostic market

COVID-19 has positively affected the market. Market players are launching different products for the detection of the SARS-CoV virus. There is an increase in approval of products by regulatory bodies after post COVID-19, which leads to an increase in market growth.

Recent Development

  • In March 2021, Luminex Corporation. A Diasorin Company received FDA Emergency Use Authorization and CE mark for expanded NxTAG respiratory panel test. This approval has helped the company to increase its revenue.

Syndromic Multiplex Diagnostic Market Scope

The syndromic multiplex diagnostic market is categorized into five segments: product and services, infection type, disease, panels type, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

  • Reagents & Consumables
  • Instruments, Software & Accessories
  • Services

Based on products and services, the North America syndromic multiplex diagnostic market is segmented into reagents & consumables, instruments, software & accessories and services.

Infection Type

  • Viral
  • Bacterial
  • Parasites
  • Fungal

Based on infection type, the North America syndromic multiplex diagnostic market is segmented into viral, bacterial, parasites and fungal.

Disease

Based on disease, the North America syndromic multiplex diagnostic market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis meningitis and others.

Panels Type

  • Respiratory Panel
  • GI-Enteric Panel
  • Sexually Transmitted Disease Panel
  • Blood-Sepsis Panel
  • Meningitis Panel
  • Others

Based on panels type, the North America syndromic multiplex diagnostic market is segmented into respiratory panel, GI-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel and others.

End User

  • Hospitals
  • Clinical Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Others

Marché du diagnostic multiplex syndromique

En fonction de l’utilisateur final, le marché nord-américain du diagnostic multiplex syndromique est segmenté en laboratoires cliniques, hôpitaux, sociétés pharmaceutiques et biotechnologiques, instituts de recherche et autres.

Analyse/perspectives régionales du marché du diagnostic multiplex syndromique

Le marché du diagnostic multiplex syndromique est analysé et des informations et tendances sur la taille du marché sont fournies par pays, produit et services, type d’infection, maladie, type de panels et utilisateur final comme référencé ci-dessus.

Les pays couverts par le rapport sont les États-Unis, le Canada et le Mexique.

Le marché américain du diagnostic syndromique multiplex devrait croître en raison de l’augmentation de la prévalence des maladies infectieuses et de la hausse de la demande de diagnostic précoce et précis.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse des parts de marché du diagnostic multiplex syndromique

Le paysage concurrentiel du marché du diagnostic multiplex syndromique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Arabie saoudite, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché du diagnostic multiplex syndromique.

Français Certains des principaux acteurs opérant sur le marché nord-américain du diagnostic multiplex syndromique sont BioFire Diagnostics (une filiale de bioMérieux SA), Seegene Inc., Luminex Corporation. A DiaSorin Company, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid (une filiale de Danaher), QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Akonni Biosystems, Inc., Biocartis, QuantuMDx Group Ltd., Applied BioCode, Inc., Prominex Inc., Nanomix, Inc., Curetis (une filiale d'OpGen, Inc.) entre autres.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT AND SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES

4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021)

5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES

6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES

6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING

6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS

6.2 RESTRAINTS

6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS

6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE

6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS

6.4 CHALLENGES

6.4.1 PRODUCT RECALLS

6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS

7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES

7.1 OVERVIEW

7.2 REAGENTS & CONSUMABLES

7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES

7.4 SERVICES

8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE

8.1 OVERVIEW

8.2 VIRAL

8.2.1 CORONAVIRUS

8.2.2 INFLUENZA VIRUS

8.2.3 ADENOVIRUS

8.2.4 RHINOVIRUS

8.2.5 ROTAVIRUS

8.2.6 OTHERS

8.3 BACTERIAL

8.3.1 PNEUMONIAE

8.3.2 BORDETELLA PERTUSSIS

8.3.3 STAPHYLOCOCCUS

8.3.4 OTHERS

8.4 PARASITES

8.5 FUNGAL

9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE

9.1 OVERVIEW

9.2 RESPIRATORY INFECTIONS

9.3 GASTROENTERITIS

9.4 SEXUALLY TRANSMITTED INFECTIONS

9.5 SEPSIS

9.6 MENINGITIS

9.7 OTHERS

10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE

10.1 OVERVIEW

10.2 RESPIRATORY PANEL

10.3 GI-ENTERIC PANEL

10.4 SEXUALLY TRANSMITTED DISEASE PANEL

10.5 BLOOD-SEPSIS PANEL

10.6 MENINGITIS PANEL

10.7 OTHERS

11 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 CLINICAL LABORATORIES

11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.5 RESEARCH INSTITUTES

11.6 OTHERS

12 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION

12.1 NORTH AMERICA

12.1.1 U.S.

12.1.2 CANADA

12.1.3 MEXICO

13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMÉRIEUX SA)

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENTS

15.2 F. HOFFMANN-LA ROCHE LTD

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.3 LUMINEX CORPORATION. A DIASORIN COMPANY

15.3.1 COMPANY SNAPSHOT

15.3.2 RECENT FINANCIALS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 PRODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENT

15.4 CEPHEID (A SUBSIDIARY OF DANAHER)

15.4.1 COMPANY SNAPSHOT

15.4.2 RECENT FINANCIALS

15.4.3 COMPANY SHARE ANALYSIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENTS

15.5 QIAGEN

15.5.1 COMPANY SNAPSHOT

15.5.2 RECENT FINANCIALS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENT

15.6 ABBOTT

15.6.1 COMPANY SNAPSHOT

15.6.2 REVENUE ANALYSIS

15.6.3 PRODUCT PORTFOLIO

15.6.4 RECENT DEVELOPMENT

15.7 AKONNI BIOSYSTEMS, INC.

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 APPLIED BIOCODE, INC.

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 BD

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.1 BIOCARTIS

15.10.1 COMPANY SNAPSHOT

15.10.2 REVENUE ANALYSIS

15.10.3 PRODUCT PORTFOLIO

15.10.4 RECENT DEVELOPMENT

15.11 BIO-RAD LABORATORIES, INC.

15.11.1 COMPANY SNAPSHOT

15.11.2 REVENUE ANALYSIS

15.11.3 PRODUCT PORTFOLIO

15.11.4 RECENT DEVELOPMENT

15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH)

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENT

15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.)

15.13.1 COMPANY SNAPSHOT

15.13.2 RECENT FINANCIALS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 HOLOGIC, INC.

15.14.1 COMPANY SNAPSHOT

15.14.2 RECENT FINANCIALS

15.14.3 PRODUCT PORTFOLIO

15.14.4 RECENT DEVELOPMENT

15.15 MIRXES PTE LTD.

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 NANŌMIX, INC.

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

15.17 PROMINEX INC.

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENT

15.18 QUANTUMDX GROUP LTD.

15.18.1 COMPANY SNAPSHOT

15.18.2 PRODUCT PORTFOLIO

15.18.3 RECENT DEVELOPMENTS

15.19 SEEGENE INC.

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUE ANALYSIS

15.19.3 PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENTS

15.2 SIEMENS HEALTHCARE GMBH

15.20.1 COMPANY SNAPSHOT

15.20.2 RECENT FINANCIALS

15.20.3 PRODUCT PORTFOLIO

15.20.4 RECENT DEVELOPMENT

15.21 THERMOFISHER SCIENTIFIC INC.

15.21.1 COMPANY SNAPSHOT

15.21.2 RECENT FINANCIALS

15.21.3 PRODUCT PORTFOLIO

15.21.4 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

Liste des tableaux

TABLE 1 COST OF THE PRODUCT

TABLE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 42 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 43 U.S. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 44 U.S. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 45 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 46 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 47 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 48 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 49 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 50 CANADA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 51 CANADA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 52 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 53 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 54 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 55 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 56 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 57 MEXICO VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 58 MEXICO BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 59 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 60 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 61 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

Liste des figures

FIGURE 1 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD

FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA

FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE

FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019

FIGURE 18 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021

FIGURE 19 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION)

FIGURE 20 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029)

FIGURE 21 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE

FIGURE 22 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021

FIGURE 23 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION)

FIGURE 24 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029)

FIGURE 25 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE

FIGURE 26 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021

FIGURE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION)

FIGURE 28 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029)

FIGURE 29 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE

FIGURE 30 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021

FIGURE 31 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION)

FIGURE 32 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029)

FIGURE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE

FIGURE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021

FIGURE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 36 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)

FIGURE 37 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021)

FIGURE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021)

FIGURE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)

FIGURE 41 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)

FIGURE 42 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029)

FIGURE 43 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The North America Syndromic Multiplex Diagnostic Market will grow at a CAGR of 9.0% during the forecast by 2029.
The significant factors flourishing the growth of the North America Syndromic Multiplex Diagnostic Market are Rise in prevalence of infectious diseases, and Increase in regulatory approval for acute respiratory syndrome coronavirus testing.
The major players operating in the North America Syndromic Multiplex Diagnostic Market are BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Akonni Biosystems, Inc. (U.S.), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Applied BioCode, Inc. (U.S.), Prominex Inc. (U.S.), Nanōmix, Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany).
The major countries covered in the North America Syndromic Multiplex Diagnostic Market are U.S., Canada, and Mexico.